Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
Clinical trial NCT05883644 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05883644
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-27
- Primary completion
- 2026-03-30
- Enrollment
- 111
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.